STOCK TITAN

European marketing authorization application for MOB-015 submitted

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

STOCKHOLM, March 28, 2022 /PRNewswire/ -- Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.

Moberg Pharma have submitted a full application, which offers the possibility of data exclusivity in Europe for up to ten years following market approval. The Swedish Medical Products Agency is the reference member state and will lead the review of the application. The company's goal is to receive its first market approval and launch MOB-015 in 2023.

"Submitting the Marketing Authorization Application in Europe is a key milestone in our journey to launch a new and improved nail fungus drug. MOB-015 is uniquely positioned through its high antifungal efficacy, since there is significant need for a treatment that truly cures the nail infection," says Anna Ljung, CEO of Moberg Pharma AB.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on March 28th, 2022.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/european-marketing-authorization-application-for-mob-015-submitted,c3529030

The following files are available for download:

https://mb.cision.com/Main/1662/3529030/1551387.pdf

European marketing authorization application for MOB-015 submitted

Cision View original content:https://www.prnewswire.com/news-releases/european-marketing-authorization-application-for-mob-015-submitted-301511439.html

SOURCE Moberg Pharma

MBGRF

OTC:MBGRF

MBGRF Rankings

MBGRF Latest News

MBGRF Stock Data

0
Pharmaceuticals: Other
Health Technology
Link
SE
Bromma

About MBGRF

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. It offers products through the following brands: Kerasal, Kerasal Nail, Balmex, NewSkin, Dermoplast, Domeboro, and Fiber Choice. The company was founded by Peter Gunnar Maurits Wolpert and Marie Moberg in March 2006 and is headquartered in Bromma, Sweden.